GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis. Monday at the joint congress of the American Academy of Allergy, Asthma & Immunology and World Allergy Organization, the pharma giant rolled out data showing that switching uncontrolled Xolair patients to GSK’s Nucala improved asthma control.Original Article
Glaxo aims to lure patients from Novartis’ Xolair with Nucala switching study
